These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 481845)

  • 1. Intralesional immune therapy: methanol extraction residue of BCG or purified protein derivative.
    Lokich JJ; Garnick MB; Legg M
    Oncology; 1979; 36(5):236-41. PubMed ID: 481845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.
    Krown SE; Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Huvos AG; Oettgen HF
    Cancer; 1978 Dec; 42(6):2648-60. PubMed ID: 728866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-inventing intratumoral immunotherapy for melanoma.
    Triozzi PL; Tuthill RJ; Borden E
    Immunotherapy; 2011 May; 3(5):653-71. PubMed ID: 21554094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R; Wybran J; Epstein W
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
    Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
    Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
    Coates AS; Peters M
    Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in viral warts with intradermal
    Podder I; Bhattacharya S; Mishra V; Sarkar TK; Chandra S; Sil A; Pal S; Kumar D; Saha A; Shome K; Bandyopadhyay D; Das NK
    Indian J Dermatol Venereol Leprol; 2017; 83(3):411. PubMed ID: 27852999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of intra-lesional injection of tuberculin-active protein on metastatic nodules of human malignant melanoma].
    Saida T
    Nihon Hifuka Gakkai Zasshi; 1982 Nov; 92(13):1399-414. PubMed ID: 6984865
    [No Abstract]   [Full Text] [Related]  

  • 9. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
    de la Monte SM; Hutchins GM
    Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple cutaneous malignant melanomas with features of primary melanoma.
    Unger SW; Wanebo HJ; Cooper PH
    Ann Surg; 1981 Feb; 193(2):245-50. PubMed ID: 7469560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
    Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA; Rapp HJ
    Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCG immunotherapy in patients with malignant melanoma.
    Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
    Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility study of active immunotherapy in patients with solid tumors.
    Gerner RE; Moore GE
    Cancer; 1976 Jul; 38(1):131-43. PubMed ID: 779950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe complications of intralesional BCG therapy in an unsensitized patient. Case report and clinical implications.
    Felix EL; Jessup JM; Cohen MH
    Arch Surg; 1978 Jul; 113(7):893-6. PubMed ID: 678104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of methanol extraction residue of BCG on the cellular immune response in patients with malignant melanoma.
    Bartal A; Cohen Y; Mekori T; Haasz R; Robinson E
    Med Pediatr Oncol; 1979; 6(1):1-10. PubMed ID: 440203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulomatous lymphangitis. A complication of intralymphatic immunotherapy with methanol extraction residue of BCG (MER).
    Kirkwood JM; Ariyan S; Nordlund JJ; Forget BM
    Cancer; 1982 Oct; 50(7):1299-303. PubMed ID: 7104973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of melanoma with intralesional BCG.
    Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
    Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
    [No Abstract]   [Full Text] [Related]  

  • 19. Intralesional BCG application in malignant melanoma.
    Sopková B; Kolár V
    Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epilesional scarification. Preliminary report of a new approach to local immunotherapy with BCG.
    Richman SP; Mavligit GM; Wolk R; Gutterman JU; Hersh EM
    JAMA; 1975 Dec; 234(12):1233-5. PubMed ID: 1242748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.